Marimed (MRMD) Cash from Financing Activities (2014 - 2026)
Marimed (MRMD) posted quarterly Cash from Financing Activities of -$1.1 million for Q1 2026, up 9.21% year-over-year from -$1.0 million in Q1 2025, and down 21.08% quarter-over-quarter from -$944000.0 in Q4 2025.
Marimed (MRMD) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Marimed (MRMD) has reported Cash from Financing Activities for 13 consecutive years, with -$1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 9.21% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$4.6 million (down 5775.31% YoY), while the FY2025 annual figure was -$4.7 million, down 257.89% from the prior year.
- Cash from Financing Activities declined to -$1.1 million in Q1 2026 per MRMD's latest filing, from -$944000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $23.3 million in Q1 2023 and bottomed at -$3.1 million in Q3 2023.
- Historically, Cash from Financing Activities has averaged $1.1 million across 5 years, with a median of -$806000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 1349.15% — and 2023, when it jumped 7176.6%.
- Marimed's Cash from Financing Activities stood at -$600000.0 in 2022, then jumped by 850.0% to $4.5 million in 2023, then slumped by 119.84% to -$893000.0 in 2024, then fell by 5.71% to -$944000.0 in 2025, then slipped by 21.08% to -$1.1 million in 2026.
- Business Quant data shows MRMD's Cash from Financing Activities at -$1.1 million in Q1 2026, -$944000.0 in Q4 2025, and -$1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Marimed | 30.77 Mn | 22.33 Mn | 16.23 Mn | -1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.21 Mn |
| Jun 30, 2026 | -1.21 Mn |
| Mar 31, 2026 | -1.14 Mn |
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -944,000.00 |
| Dec 31, 2025 | -944,000.00 |
| Sep 30, 2025 | -1.70 Mn |
| Sep 30, 2025 | -1.70 Mn |
| Jun 30, 2025 | -806,000.00 |
| Jun 30, 2025 | -806,000.00 |
| Mar 31, 2025 | -1.26 Mn |
| Mar 31, 2025 | -1.26 Mn |
| Dec 31, 2024 | -893,000.00 |
| Dec 31, 2024 | -893,000.00 |
| Sep 30, 2024 | 917,000.00 |
| Sep 30, 2024 | 917,000.00 |
| Jun 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.65 Mn |